Study and baseline characteristics of studies included in the NMA
| Trial name . | ALPINE . | ELEVATE-RR . | ASCEND . |
|---|---|---|---|
| Study arms | Zanubrutinib vs Ibrutinib | Acalabrutinib vs Ibrutinib | Acalabrutinib vs BR/IR |
| Median follow-up, mo | 39 | 40.9 | 46.5 (acalabrutinib) 45.3 (BR/IR) |
| Sample size | 652 | 533 | 310 |
| Median age (range), y | 67 (35-90) | 66 (28-89) | 67 (32-90) |
| Male sex (%) | 68 | 71 | 67 |
| ECOG performance status score (%) | 0-1: 97 | 0-1: 92 | 0: 36 |
| 2: 3 | 2: 8 | 1: 51 | |
| 2: 13 | |||
| Rai stage III-IV (%) | NR | 50 | 42 |
| Binet stage∗ (%) | A: 11 | A: 11 | NR |
| B: 48 | B: 41 | ||
| C: 41 | C: 41 | ||
| del(11q) (%) | 27 | 64 | 27 |
| del(17p) (%) | 15 | 46 | 16 |
| TP53 (%) | 15 | 40 | 24 |
| del(17p) and/or TP53 (%) | 23 | 51 | 28 |
| Unmutated IGHV (%) | 73 | 86 | 74 |
| Median no. of prior lines (range) | 1 (1-8) | 2 (1-12) | 2 (1-10) |
| No. of prior lines (%) | 1: 59 | 1-3: 88 | 1: 48 |
| 2: 24 | 2: 27 | ||
| 3: 10 | 3: 13 | ||
| Prior anti-CD20 Ab (%) | 83 | 86 | 80 |
| Trial name . | ALPINE . | ELEVATE-RR . | ASCEND . |
|---|---|---|---|
| Study arms | Zanubrutinib vs Ibrutinib | Acalabrutinib vs Ibrutinib | Acalabrutinib vs BR/IR |
| Median follow-up, mo | 39 | 40.9 | 46.5 (acalabrutinib) 45.3 (BR/IR) |
| Sample size | 652 | 533 | 310 |
| Median age (range), y | 67 (35-90) | 66 (28-89) | 67 (32-90) |
| Male sex (%) | 68 | 71 | 67 |
| ECOG performance status score (%) | 0-1: 97 | 0-1: 92 | 0: 36 |
| 2: 3 | 2: 8 | 1: 51 | |
| 2: 13 | |||
| Rai stage III-IV (%) | NR | 50 | 42 |
| Binet stage∗ (%) | A: 11 | A: 11 | NR |
| B: 48 | B: 41 | ||
| C: 41 | C: 41 | ||
| del(11q) (%) | 27 | 64 | 27 |
| del(17p) (%) | 15 | 46 | 16 |
| TP53 (%) | 15 | 40 | 24 |
| del(17p) and/or TP53 (%) | 23 | 51 | 28 |
| Unmutated IGHV (%) | 73 | 86 | 74 |
| Median no. of prior lines (range) | 1 (1-8) | 2 (1-12) | 2 (1-10) |
| No. of prior lines (%) | 1: 59 | 1-3: 88 | 1: 48 |
| 2: 24 | 2: 27 | ||
| 3: 10 | 3: 13 | ||
| Prior anti-CD20 Ab (%) | 83 | 86 | 80 |
Ab, antibody; IGHV, immunoglobulin heavy-chain variable region gene; NR, not reported.
Defined only for patients with CLL (percentage of categories reported are for the Binet stages among patients with CLL, in which ALPINE had 623 patients with CLL). Unknown or not done made the missing category, percentage of which is not presented here.